Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + CAPEOX Neoadjuvant Therapy for MSI-H/dMMR Locally Advanced Colon Cancer
NCT04389151Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in colon cancer, sponsored by First Affiliated Hospital of Xiamen University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04389151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389151.